[go: up one dir, main page]

MX2015001648A - Composiciones que comprenden derivados de espicamicina y metodos de uso de los mismos. - Google Patents

Composiciones que comprenden derivados de espicamicina y metodos de uso de los mismos.

Info

Publication number
MX2015001648A
MX2015001648A MX2015001648A MX2015001648A MX2015001648A MX 2015001648 A MX2015001648 A MX 2015001648A MX 2015001648 A MX2015001648 A MX 2015001648A MX 2015001648 A MX2015001648 A MX 2015001648A MX 2015001648 A MX2015001648 A MX 2015001648A
Authority
MX
Mexico
Prior art keywords
compositions
methods
spicamycin derivatives
spicamycin
derivatives
Prior art date
Application number
MX2015001648A
Other languages
English (en)
Inventor
Mary Katherine Delmedico
Michael Radomsky
Linda Jett
Original Assignee
Dara Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dara Biosciences Inc filed Critical Dara Biosciences Inc
Publication of MX2015001648A publication Critical patent/MX2015001648A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se refiere a composiciones que comprenden derivados de espicamicina, métodos para elaborar tales composiciones, y su uso en el tratamiento y/o prevención de dolor, que incluye dolor neuropático.
MX2015001648A 2012-08-09 2013-08-08 Composiciones que comprenden derivados de espicamicina y metodos de uso de los mismos. MX2015001648A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201261681385P 2012-08-09 2012-08-09
US201261730311P 2012-11-27 2012-11-27
US201261736138P 2012-12-12 2012-12-12
PCT/US2013/054100 WO2014025979A1 (en) 2012-08-09 2013-08-08 Compositions comprising spicamycin derivatives and methods of use thereof

Publications (1)

Publication Number Publication Date
MX2015001648A true MX2015001648A (es) 2015-10-14

Family

ID=48998737

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015001648A MX2015001648A (es) 2012-08-09 2013-08-08 Composiciones que comprenden derivados de espicamicina y metodos de uso de los mismos.

Country Status (10)

Country Link
US (3) US9078910B2 (es)
EP (1) EP2882418A1 (es)
JP (1) JP2015524482A (es)
KR (1) KR20150038572A (es)
CN (1) CN104822369A (es)
AU (1) AU2013299560A1 (es)
CA (1) CA2880853A1 (es)
MX (1) MX2015001648A (es)
NZ (1) NZ704342A (es)
WO (1) WO2014025979A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015061481A1 (en) * 2013-10-23 2015-04-30 Dara Biosciences, Inc. Methods of treating liquid tumors using compositions comprising spicamycin derivatives
WO2015153961A1 (en) * 2014-04-03 2015-10-08 Yan-Yeung Luk Synthetic disugar hydrocarbons as natural analogos to control microbial behaviors
KR101779135B1 (ko) 2016-04-05 2017-09-18 경북대학교 산학협력단 덱사메타손과 이부프로펜을 유효성분으로 포함하는 신경병증성 통증 예방 및 치료용 약학적 조성물
CN110628937A (zh) * 2019-10-28 2019-12-31 华中农业大学 玉米基因krn5在提高玉米产量中的应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2783722B2 (ja) 1991-07-12 1998-08-06 麒麟麦酒株式会社 スピカマイシン誘導体およびそれを含む抗腫瘍剤
JP3066291B2 (ja) * 1994-07-07 2000-07-17 麒麟麦酒株式会社 抗腫瘍薬物の用時調合型セット製剤
US5905069A (en) * 1998-01-26 1999-05-18 The General Hospital Corporation Methods of decreasing or preventing pain using spicamycin or derivatives thereof
EP1328236B1 (en) 2000-09-20 2011-04-06 The General Hospital Corporation Methods of decreasing or preventing pain using spicamycin derivatives
US9248098B2 (en) * 2008-10-10 2016-02-02 Dara Biosciences, Inc. Treating or preventing pain using spicamycin derivatives

Also Published As

Publication number Publication date
US20140045780A1 (en) 2014-02-13
US9078910B2 (en) 2015-07-14
CA2880853A1 (en) 2014-02-13
JP2015524482A (ja) 2015-08-24
KR20150038572A (ko) 2015-04-08
AU2013299560A1 (en) 2015-02-26
US20150297721A1 (en) 2015-10-22
NZ704342A (en) 2016-04-29
WO2014025979A1 (en) 2014-02-13
US20160279160A1 (en) 2016-09-29
CN104822369A (zh) 2015-08-05
EP2882418A1 (en) 2015-06-17

Similar Documents

Publication Publication Date Title
PH12014501738A1 (en) Piperidino-pyrimidine derivatives for the treatment of viral infections
IN2015DN02634A (es)
ZA201403948B (en) Antimicrobial compositions comprising dgla, 15-ohepa and/or 15-hetre and methods of use thereof
PH12015500724A1 (en) 1, 2, 4-triazine derivatives for the treatment of viral infections
MX2011014019A (es) Derivados de diazahomoadamantano y sus metodos de uso.
MX356755B (es) Compuestos de tipo fumagilol y metodos para su elaboración y uso.
PH12018501279A1 (en) Compositions comprising 15-hepe and methods of using the same
HK1204928A1 (en) Inhibitors of the notch signalling pathway and secretion for use in medicine
PH12016500495A1 (en) Compositions for the treatment of hypertension and/or fibrosis
IN2014DN07326A (es)
ZA201501494B (en) Sirna and their use in methods and compositions for the treatment and/or prevention of eye conditions
PH12012501548A1 (en) Compositions comprising sugar-cysteine products
MX2015001648A (es) Composiciones que comprenden derivados de espicamicina y metodos de uso de los mismos.
MX2015013755A (es) Formulacion farmaceutica para uso en el tratamiento y/o prevencion de restenosis.
UA117567C2 (uk) Композиція, яка стимулює лактацію, на основі фосфатидилсерину
PL3041459T3 (pl) Kompozycje przydatne w zapobieganiu lub leczeniu raka skóry
ZA201502181B (en) Sirna and their use in methods and compositions for the treatment and/or prevention of eye conditions
PT2862576T (pt) Microrganismos e composições que os compreendem para utilização no tratamento ou prevenção de mastite
MX360885B (es) Nuevas composiciones antifungicas.
MX2012010006A (es) Agonistas de a3ar para el tratamiento de uveitis.